Caris Life Sciences launches Caris ChromoSeq tumor profiling assay

Caris Life Sciences (CAI) announced the launch of Caris ChromoSeq, a Whole Genome Sequencing and Whole Transcriptome assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia, or AML, myelodysplastic syndromes, or MDS, and myeloproliferative neoplasms, or MPN, as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded. Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician’s overall clinical and pathological evaluation. The test delivers approximately 250x read depth across the genome with 40 million transcriptome read. Results are synthesized into a single report to support clinical decision-making, with an expected seven-day turnaround time.